Free tool
FAERS Monitor: Cerezyme
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 020367 or its brand name (Cerezyme, Imiglucerase). Reports on generic versions are filed under their own applications.
Reports
4,775
Serious
3,317
69% of reports
Hospitalization
1,476
Death reported
821
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia216
- fatigue192
- death174
- fall174
- pneumonia174
- weight increased163
- exposure during pregnancy162
- dyspnoea151
- bone pain150
- weight decreased140
- malaise137
- arthralgia130
- disease progression129
- pain123
- condition aggravated117
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 115 |
| 2005 | 105 |
| 2006 | 123 |
| 2007 | 164 |
| 2008 | 170 |
| 2009 | 233 |
| 2010 | 225 |
| 2011 | 262 |
| 2012 | 172 |
| 2013 | 230 |
| 2014 | 386 |
| 2015 | 273 |
| 2016 | 226 |
| 2017 | 277 |
| 2018 | 213 |
| 2019 | 202 |
| 2020 | 146 |
| 2021 | 201 |
| 2022 | 225 |
| 2023 | 213 |
| 2024 | 196 |
| 2025 | 226 |
| 2026 | 192 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,384 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| exposure during pregnancySignal | 162 | 11.5 | 9.9 | 1,545 |
| bone painSignal | 150 | 11.3 | 9.7 | 1,399 |
| disease progressionSignal | 129 | 4.8 | 4.1 | 387 |
| weight increasedSignal | 163 | 3.2 | 2.8 | 248 |
| pyrexiaSignal | 216 | 2.8 | 2.4 | 243 |
| pneumoniaSignal | 174 | 2.4 | 2.0 | 138 |
| fallSignal | 174 | 2.3 | 2.0 | 129 |
| weight decreasedSignal | 140 | 2.2 | 1.9 | 93 |
| condition aggravated | 117 | 1.7 | 1.4 | 33 |
| arthralgia | 130 | 1.4 | 1.2 | 13 |
| malaise | 137 | 1.4 | 1.2 | 14 |
| dyspnoea | 151 | 1.2 | 1.0 | 4 |
| fatigue | 192 | 1.1 | 0.9 | 1 |
| death | 174 | 0.9 | 0.8 | 2 |
| pain | 123 | 0.9 | 0.7 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.